Welcome to our dedicated page for CXApp SEC filings (Ticker: CXAIW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CXApp's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CXApp's regulatory disclosures and financial reporting.
CXApp Inc. filed a Form S-3 shelf registration that permits offers of up to $150,000,000 of common stock, preferred stock, subscription rights, units and warrants and includes a separate at-the-market sales agreement allowing up to $7,959,040 of common stock sales through Maxim Group LLC at a fixed commission of 3.0%. As of August 8, 2025, CXApp reported 23,435,234 shares outstanding (approximately 21,318,858 held by non-affiliates) and an aggregate market value of non-affiliate shares of approximately $23,877,120. The prospectus discloses strategic priorities in fiscal 2025 emphasizing AI-driven product development, expansion into enterprise customers and cost discipline.
The filing discloses material risk items including a history of operating losses, identified material weaknesses in internal control over financial reporting, Nasdaq listing and delisting risk, and that public warrants (10,751,862) and private placement warrants (10,280,000) remain outstanding with public warrant exercise price at $11.50 (public common share price reported at $0.9263 on Aug 5, 2025).